Article Text

Download PDFPDF
Randomised controlled trial
Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests ATC is a medical consultant, and has received consultancy and clinical trial funding from pharmaceutical companies, including Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Daiichi, GSK, Johnson & Johnson, Mitsubishi Pharma, Pfizer, Portola, Sanofi-aventis, Schering-Plough and Takeda. ATC is an advisor on VTE prevention to the UK Government Health Select Committee, the All-Party Working Group on Thrombosis, the Department of Health and the NHS. ATC is also an advisor to Lifeblood: The Thrombosis Charity and is the founder of the European educational charity the Coalition to Prevent VTE.

  • Provenance and peer review Not commissioned; externally peer reviewed.